{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:02Z","timestamp":1792786142515,"version":"4.5.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"University of Auckland","id":[{"id":"https:\/\/ror.org\/03b94tp07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to estimate the direct health care cost burden of herpes zoster ophthalmicus (HZO) in New Zealand and to evaluate potential implications for shingles vaccination policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed 869 participants with HZO treated at Greenlane Eye Clinic, Auckland, using data from the Auckland Zoster Study. Clinical and demographic data were reviewed and cross-referenced with hospital electronic databases. The total number of hospital visits, medications, and procedures associated with HZO and its complications were recorded. Unit costs were derived from New Zealand pricing data, and cumulative hospital-based direct health care costs were calculated. Factors associated with health care costs were evaluated using a generalized linear model (GLM) with a gamma distribution and log link, with multivariable linear regression performed as a sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median follow-up was 6.3 years [IQR 3.7\u20138.9]. The average hospital-based health care cost captured in this study was New Zealand dollars $3185.95 \u00b1 6791.22 (range $30.49\u2013$85,967.59). Mean inpatient, outpatient, drug, and procedure costs were $278.82 \u00b1 1628.79, $2231.16 \u00b1 3762.62, $113.51 \u00b1 1288.57, and $562.45 \u00b1 2582.89, respectively. In multivariable GLM analysis, higher health care costs were independently associated with older age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), immunosuppression (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047), uveitis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), optic neuropathy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and recurrent disease (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>HZO imposes a significant direct health care cost burden on the New Zealand health care system. These findings provide important local cost data for future economic evaluations, including cost-effectiveness analyses of HZ prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ico.0000000000004342","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:00:20Z","timestamp":1791399620000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Economic Burden of Herpes Zoster Ophthalmicus in New Zealand: A Retrospective Cohort Cost Analysis"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-4707","authenticated-orcid":false,"given":"Priya Darshni","family":"Samalia","sequence":"first","affiliation":[{"name":"University of Auckland, Auckland, New Zealand;"},{"name":"Te Whatu Ora Te Toka Tumai\/Health New Zealand Auckland, New Zealand; and"},{"name":"University of Otago, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Lian","family":"Ji","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Meyer","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael Louise","family":"Niederer","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand;"},{"name":"Te Whatu Ora Te Toka Tumai\/Health New Zealand Auckland, New Zealand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"R1-20261007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","article-title":"Meta-regression of Herpes Zoster incidence worldwide","volume":"11","author":"Curran","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R2-20261007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2021.02.002","article-title":"Herpes Zoster ophthalmicus clinical presentation and risk factors for loss of vision","volume":"226","author":"Niederer","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R3-20261007","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2024.09.017","article-title":"Herpes Zoster ophthalmicus uveitis: onset and complications","volume":"268","author":"Meyer","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R4-20261007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","article-title":"Aggregate health and economic burden of Herpes zoster in the United States: illustrative example of a pain condition","volume":"161","author":"Harvey","year":"2020","journal-title":"Pain"},{"key":"R5-20261007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","article-title":"Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older","volume":"27","author":"Stein","year":"2009","journal-title":"Vaccine"},{"key":"R6-20261007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and Herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J Infect"},{"key":"R7-20261007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40801-017-0119-4","article-title":"Economic burden of Herpes Zoster and post-herpetic neuralgia in adults 60 years of age or older: results from a prospective, physician practice-based cohort study in Kushiro, Japan","volume":"4","author":"Nakamura","year":"2017","journal-title":"Drugs Real World Outcomes"},{"key":"R8-20261007","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20261007","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted Herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20261007","doi-asserted-by":"crossref","first-page":"25151355221084535","DOI":"10.1177\/25151355221084535","article-title":"Global Herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccin Immunother"},{"key":"R12-20261007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health care utilization and cost burden of Herpes zoster in a community population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R13-20261007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4236\/wjv.2012.23022","article-title":"The burden of hospitalisation for Herpes Zoster ophtalmicus in Spain (1997-2008)","volume":"02","author":"Gil-Prieto","year":"2012","journal-title":"World J Vaccin"},{"key":"R14-20261007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12889-015-1514-y","article-title":"The humanistic, economic and societal burden of Herpes zoster in Europe: a critical review","volume":"15","author":"Gater","year":"2015","journal-title":"BMC Public Health"},{"key":"R15-20261007","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12879-015-1059-9","article-title":"Burden of herpes zoster: the direct and comorbidity costs of Herpes zoster events in hospitalized patients over 50 years in France","volume":"15","author":"Blein","year":"2015","journal-title":"BMC Infect Dis"},{"key":"R16-20261007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcjo.2017.08.005","article-title":"Treatment of Herpes zoster ophthalmicus: a systematic review and Canadia cost-comparison","volume":"53","author":"Fan","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"R17-20261007","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40520-019-01374-5","article-title":"Vaccination for quality of life: Herpes-zoster vaccines","volume":"33","author":"Lang","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"R18-20261007","doi-asserted-by":"crossref","first-page":"e021241","DOI":"10.1136\/bmjopen-2017-021241","article-title":"Quantifying the incidence and burden of Herpes zoster in New Zealand general practice: a retrospective cohort study using a natural language processing software inference algorithm","volume":"8","author":"Turner","year":"2018","journal-title":"BMJ Open"},{"key":"R19-20261007","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3181d31e5c","article-title":"Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study","volume":"74","author":"Lin","year":"2010","journal-title":"Neurology"},{"key":"R20-20261007","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014","volume":"20","author":"Mu\u00f1oz-Quiles","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R21-20261007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4161\/hv.36160","article-title":"Evaluation of the economic burden of Herpes Zoster (HZ) infection","volume":"11","author":"Panatto","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R22-20261007","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of Herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Care Res"},{"key":"R23-20261007","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of Herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R24-20261007","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R25-20261007","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of Herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R26-20261007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4065\/mcp.2010.0618","article-title":"Herpes zoster recurrences more frequent than previously reported","volume":"86","author":"Yawn","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R27-20261007","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1161\/STROKEAHA.109.562017","article-title":"Increased risk of stroke after a Herpes zoster attack: a population-based follow-up study","volume":"40","author":"Kang","year":"2009","journal-title":"Stroke"},{"key":"R28-20261007","doi-asserted-by":"crossref","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"R29-20261007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"key":"R30-20261007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ophtha.2012.09.007","article-title":"Incidence of Herpes zoster ophthalmicus: results from the Pacific ocular inflammation study","volume":"120","author":"Borkar","year":"2013","journal-title":"Ophthalmology"},{"key":"R31-20261007","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of Herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"R32-20261007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2011.607482","article-title":"Work and productivity loss related to Herpes zoster","volume":"14","author":"Singhal","year":"2011","journal-title":"J Med Econ"},{"key":"R33-20261007","doi-asserted-by":"crossref","first-page":"2131167","DOI":"10.1080\/21645515.2022.2131167","article-title":"Economic burden of Herpes zoster in Latin America: a systematic review and meta-analysis","volume":"18","author":"Javier Balan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R34-20261007","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of Herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"R35-20261007","first-page":"207","article-title":"The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study","volume":"8","author":"Friesen","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"R36-20261007","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/infdis\/jiaa083","article-title":"The adjuvanted recombinant zoster vaccine in adults aged \u226565 years previously vaccinated with a live-attenuated Herpes Zoster vaccine","volume":"224","author":"Dagnew","year":"2021","journal-title":"J Infect Dis"},{"key":"R37-20261007","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ophtha.2007.10.015","article-title":"Preventing Herpes zoster through vaccination","volume":"115","author":"Gelb","year":"2008","journal-title":"Ophthalmology"},{"key":"R38-20261007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40273-018-0735-1","article-title":"Cost-effectiveness of Herpes Zoster vaccination: a systematic review","volume":"37","author":"Chiyaka","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"R39-20261007","doi-asserted-by":"crossref","first-page":"2168952","DOI":"10.1080\/21645515.2023.2168952","article-title":"Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review","volume":"19","author":"Giannelos","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"R40-20261007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaophthalmol.2024.6114","article-title":"Low-dose valacyclovir in Herpes Zoster ophthalmicus: the zoster eye disease randomized clinical trial","volume":"143","author":"Cohen","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"R41-20261007","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against Herpes zoster in England and Wales","volume":"27","author":"van Hoek","year":"2009","journal-title":"Vaccine"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:00:26Z","timestamp":1791399626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000004342","relation":{},"ISSN":["0277-3740","1536-4798"],"issn-type":[{"value":"0277-3740","type":"print"},{"value":"1536-4798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"2026-01-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}